Track 01 of 9
Inflammatory Bowel Disease
Crohn’s, UC, biologics, JAK inhibitors and treat-to-target.
IBD therapeutics have entered a multi-mechanism era, with selective IL-23 inhibitors (risankizumab, mirikizumab), the S1P receptor modulator etrasimod, and the JAK1-selective upadacitinib joining established anti-TNFs and vedolizumab. STRIDE-II treat-to-target endpoints — clinical remission, biomarker normalization, and endoscopic healing — are reshaping monitoring, with intestinal ultrasound and fecal calprotectin replacing repeat colonoscopy in many programs. Sessions will examine head-to-head positioning (SEQUENCE, VEGA), perianal Crohn’s, pouchitis after IPAA, and the operationalization of therapeutic drug monitoring.
Focus areas
- IL-23 inhibitors: risankizumab and mirikizumab in moderate-to-severe disease
- Etrasimod (S1P modulator) and upadacitinib (JAK1) positioning
- STRIDE-II treat-to-target and intestinal ultrasound monitoring
- Head-to-head trials: SEQUENCE, VEGA combination induction
- Perianal Crohn’s disease and stem-cell therapy (darvadstrocel)
- Therapeutic drug monitoring for anti-TNFs and vedolizumab
- Pouchitis and chronic antibiotic-refractory pouch inflammation